AI Eye Cancer Detection Startup Eyedentity Raises €1.3M

Stockholm-based Eyedentity has successfully closed an oversubscribed seed funding round, securing €1.3 million (SEK 15 million). This capital infusion is earmarked for advancing regulatory approvals, enhancing its artificial intelligence-driven diagnostic platform, and expanding its reach into optometric practices, eye care clinics, and hospitals. The investment was spearheaded by Norrsken Launcher, with significant contributions from Karolinska Institutet Innovation and a cohort of private angel investors.

Eyedentity's innovative technology leverages AI to scrutinize fundus images, which are routinely captured during standard eye examinations. The platform is designed to identify early indicators of serious eye conditions, including uveal melanoma, a rare but aggressive form of eye cancer. This form of cancer presents a diagnostic challenge due to its potential to mimic benign conditions, making early and accurate detection paramount. The company's approach integrates seamlessly into existing optician workflows, offering a crucial decision-support tool for practitioners.

The broader MedTech and AI diagnostics sector in Europe is experiencing robust investor interest. Recent funding rounds highlight this trend, with companies like ScreenPoint Medical raising €13.6 million for breast cancer imaging AI, Moonlight AI securing €2.8 million, TidalSense garnering €16.6 million for respiratory diagnostics, neuroClues receiving €10 million for neurodiagnostics, and ShanX Medtech closing €24 million. In Sweden alone, MedVasc recently raised €2.2 million for its anesthesia catheter technology. Collectively, these recent financings underscore a strong market appetite for innovations in medical imaging and early disease detection.

The founding team of Eyedentity brings a potent blend of expertise. Gustav Stålhammar, co-founder and Chief Scientific Officer, is an ocular oncologist at St. Erik Eye Hospital and a Professor at Karolinska Institutet. Complementing this clinical insight is co-founder and CEO Mats Holmström, a machine learning engineer with prior experience at RaySearch Laboratories, where he focused on AI applications in cancer care automation. This interdisciplinary foundation is critical for developing a clinically validated and commercially viable diagnostic solution.

Anna Fredrixon, Partner at Norrsken Launcher, emphasized the unique value proposition of Eyedentity's technology. "This is a clear example of technology that can save lives but, unlike other AI companies, does not send more patients to an already overburdened healthcare system. This is a win-win. And what’s more, no new infrastructure is needed. It’s brilliant, and ready to roll out now," she stated, highlighting the platform's efficiency and minimal disruption to existing healthcare pathways.

Eyedentity's strategic advantage lies in its ability to utilize the vast number of images already generated in optician settings. As opticians increasingly manage a wider spectrum of patient concerns, from vision issues to dry eye, Eyedentity's AI provides an accessible and efficient method for enhanced screening. The company's affiliation with the Karolinska Institutet Innovation Incubator further bolsters its development, offering comprehensive support in business strategy, financing, and investor relations, facilitating crucial connections like the one with Norrsken Launcher.